Literature DB >> 9284088

HIV-1 protein gp120 crosses the blood-brain barrier: role of adsorptive endocytosis.

W A Banks1, A J Kastin, V Akerstrom.   

Abstract

HIV-1 infects the brain and leads to AIDS dementia complex. The viral coat glycoprotein, gp120, may facilitate the passage of HIV-1 and HIV-infected immune cells across the blood-brain barrier (BBB). Since the endothelial cells of the BBB do not possess the CD4 or galactosylceramide binding sites used by gp120 to induce HIV-1 uptake into other cell types, how gp120 mediates entry into brain is unknown. We postulate that gp120 crosses the BBB and does so by acting as a weak lectin to induce adsorptive endocytosis (AE) in a fashion similar to other glycoproteins like wheatgerm agglutinin (WGA). We found in vivo that gp120 crosses the BBB and its passage is enhanced 18.7-fold by WGA. In vitro studies confirm that WGA enhances uptake of gp120 by brain endothelia; most of the uptake is membrane-associated, as expected in AE. Uptake is not dependent on clatharin, caveolae, calcium channels, or endosomal acidification. Our results suggest that gp120 crosses the BBB and does so by acting as a lectin to induce AE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284088     DOI: 10.1016/s0024-3205(97)00597-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  30 in total

Review 1.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 2.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

3.  Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis.

Authors:  L M Dallasta; L A Pisarov; J E Esplen; J V Werley; A V Moses; J A Nelson; C L Achim
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 4.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 5.  In vitro methods in the study of viral and prion permeability across the blood-brain barrier.

Authors:  Ryota Nakaoke; William A Banks
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 6.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 7.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

8.  Antibody blood-brain barrier efflux is modulated by glycan modification.

Authors:  John M Finke; Kari R Ayres; Ryan P Brisbin; Hali A Hill; Emily E Wing; William A Banks
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-06-15       Impact factor: 3.770

9.  Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by the p38 mitogen-activated protein kinase pathway.

Authors:  Shinya Dohgu; William A Banks
Journal:  Exp Neurol       Date:  2008-01-19       Impact factor: 5.330

10.  Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability.

Authors:  Supriya D Mahajan; Ravikumar Aalinkeel; Donald E Sykes; Jessica L Reynolds; B Bindukumar; Stanley F Fernandez; Ramnik Chawda; Thomas C Shanahan; Stanley A Schwartz
Journal:  J Clin Immunol       Date:  2008-06-24       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.